Cargando…

Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations

BACKGROUND: Despite immune checkpoint inhibitors (ICI) being widely used to treat patients with advanced non-small cell lung cancer (NSCLC), few studies examine the role of ICI in patients with proto-oncogene B-Raf, serine/threonine kinase (BRAF) mutations. METHODS: A retrospective study was conduct...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Haowei, Cheng, Lei, Zhao, Chao, Zhou, Fei, Jiang, Tao, Guo, Haoyue, Shi, Jinpeng, Chen, Peixin, Tang, Zhuoran, Mao, Shiqi, Jia, Keyi, Ye, Lingyun, Cai, Chenlei, Li, Xuefei, Chen, Xiaoxia, Zhou, Caicun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989805/ https://www.ncbi.nlm.nih.gov/pubmed/36895926 http://dx.doi.org/10.21037/tlcr-22-613

Ejemplares similares

Single-Cell Profiling of Tumor-Associated Neutrophils in Advanced Non-Small Cell Lung Cancer
por: Shi, Jinpeng, et al.
Publicado: (2023)

Computational recognition of LncRNA signatures in tumor-associated neutrophils could have implications for immunotherapy and prognostic outcome of non-small cell lung cancer
por: Tang, Zhuoran, et al.
Publicado: (2022)

The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Wang, Haowei, et al.
Publicado: (2021)

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
por: Zhuang, Xibin, et al.
Publicado: (2019)

Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy
por: Wang, Haowei, et al.
Publicado: (2022)

Combinational immunotherapy based on immune checkpoints inhibitors in small cell lung cancer: is this the beginning to reverse the refractory situation?
por: Guo, Haoyue, et al.
Publicado: (2020)

Clinicopathologic characteristics and outcomes of Chinese patients with non‐small‐cell lung cancer and BRAF mutation
por: Ding, Xi, et al.
Publicado: (2017)

Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations
por: Obaid, Nourah Mohammad, et al.
Publicado: (2017)

Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation
por: Caliò, Anna, et al.
Publicado: (2016)

Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer
por: Qiao, Meng, et al.
Publicado: (2022)

Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation
por: Mao, Shiqi, et al.
Publicado: (2023)

Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China
por: Li, Xuefei, et al.
Publicado: (2016)

DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer
por: Dai, Jiawei, et al.
Publicado: (2021)

Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases
por: Wang, Haowei, et al.
Publicado: (2023)

Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study
por: Zhou, Fei, et al.
Publicado: (2022)

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
por: Deng, Juan, et al.
Publicado: (2019)

Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations
por: Giunta, Emilio Francesco, et al.
Publicado: (2020)

Utility of BRAF VE1 Immunohistochemistry as a Screening Tool for Colorectal Cancer Harboring BRAF V600E Mutation
por: Kwon, Jeong-Hwa, et al.
Publicado: (2018)

Papillary thyroid cancer organoids harboring BRAF(V600E) mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies
por: Chen, Dong, et al.
Publicado: (2023)

The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review
por: Liu, Yu, et al.
Publicado: (2021)

YAP1 expression is associated with survival and immunosuppression in small cell lung cancer
por: Chen, Peixin, et al.
Publicado: (2023)

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients
por: Li, Xuefei, et al.
Publicado: (2014)

Identification of recurrent USP48 and BRAF mutations in Cushing’s disease
por: Chen, Jianhua, et al.
Publicado: (2018)

Exosomes transmit T790M mutation‐induced resistance in EGFR‐mutant NSCLC by activating PI3K/AKT signalling pathway
por: Liu, Xiaozhen, et al.
Publicado: (2020)

Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma
por: Jiang, Tao, et al.
Publicado: (2019)

An immune-based risk-stratification system for predicting prognosis in pulmonary sarcomatoid carcinoma (PSC)
por: Guo, Haoyue, et al.
Publicado: (2021)

BRAF Mutation as a Potential Therapeutic Target for Checkpoint Inhibitors: A Comprehensive Analysis of Immune Microenvironment in BRAF Mutated Colon Cancer
por: Cen, Shuyi, et al.
Publicado: (2021)

RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation
por: Le Calvez, Baptiste, et al.
Publicado: (2020)

Artificial intelligence-based analysis for immunohistochemistry staining of immune checkpoints to predict resected non-small cell lung cancer survival and relapse
por: Guo, Haoyue, et al.
Publicado: (2021)

Author Correction: Identification of recurrent USP48 and BRAF mutations in Cushing’s disease
por: Chen, Jianhua, et al.
Publicado: (2023)

Pan‐cancer analysis identifies TERT alterations as predictive biomarkers for immune checkpoint inhibitors treatment
por: Jiang, Tao, et al.
Publicado: (2020)

High discrepancy in thrombotic events in non-small cell lung cancer patients with different genomic alterations
por: Liu, Yiwei, et al.
Publicado: (2021)

Challenges and countermeasures of thoracic oncology in the epidemic of COVID-19
por: Guo, Haoyue, et al.
Publicado: (2020)

Association of CD8 T cell apoptosis and EGFR mutation in non‐small lung cancer patients
por: Zhao, Chao, et al.
Publicado: (2020)

Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases
por: Qiao, Meng, et al.
Publicado: (2021)

Claudin-1 Expression Is Elevated in Colorectal Cancer Precursor Lesions Harboring the BRAF V600E Mutation()()
por: Caruso, Maria, et al.
Publicado: (2014)

Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation
por: Čepulytė, Rūta, et al.
Publicado: (2020)

Non‐small cell lung cancer in China
por: Chen, Peixin, et al.
Publicado: (2022)

Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC
por: Liu, Sangtian, et al.
Publicado: (2021)

Adenocarcinoma of High-Grade Patterns Associated with Distinct Outcome of First-Line Chemotherapy or EGFR-TKIs in Patients of Relapsed Lung Cancer
por: Yu, Xiaofei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bjl26g8brvtg5jqt1hhb6pt8uv